TuHURA Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Three initial patients with deep-seated metastatic MCC had confirmed responses sustained through week 24 after IFx-2.0 plus checkpoint therapy; no serious adverse events were reported across four treated patients. The 9–12-patient study is intended to inform feasibility, safety and potential FDA discussions.
-
The meeting covered director elections, share issuance, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and the Board's recommended three-year frequency for compensation votes was adopted.
-
The company is advancing a phase III trial for frontline Merkel cell carcinoma with FDA support, targeting accelerated approval and leveraging novel immunotherapy platforms. Additional programs include a VISTA-inhibiting antibody for AML and innovative ADCs, with key data and regulatory milestones expected within the next year.